Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-22T17:08:15.421Z Has data issue: false hasContentIssue false
  • English
  • Français

NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances

Published online by Cambridge University Press:  25 June 2020

Pilar Pinilla-Dominguez Open the ORCID record for Pilar Pinilla-Dominguez [Opens in a new window] ,
Huseyin Naci ,
Leeza Osipenko  and
Elias Mossialos
Pilar Pinilla-Dominguez*
Affiliation:
Scientific Advice, National Institute for Health and Care Excellence (NICE), London, UK
Huseyin Naci
Affiliation:
LSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK
Leeza Osipenko
Affiliation:
LSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK
Elias Mossialos
Affiliation:
LSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK
*
Author for correspondence: Pilar Pinilla-Dominguez, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

To investigate the impact of the uncertainty stemming from products with European conditional marketing authorization (CMA) or authorization in exceptional circumstances (AEC) on the National Institute for Health and Care Excellence's (NICE) recommendations.

Methods

Products which received CMA/AEC by European Medicines Agency (EMA) up to 1 December 2016 were identified and matched with corresponding NICE decisions issued by August 2017, the status of which was then traced to August 2019. We assessed whether the conversion of CMA to full marketing authorization triggered a review of a NICE decision. The odds of a recommendation carrying a commercial arrangement for products with and without CMA/AEC were calculated.

Results

Fifty-four products were granted CMA/AEC by EMA. NICE conducted thirty evaluations of products with CMA/AEC. Twelve products were recommended by NICE by August 2017 and fourteen by August 2019. All recommendations had an associated commercial arrangement. The odds of carrying a commercial arrangement were higher for products with CMA/AEC compared to those with full authorization. Conversions from conditional to full authorization among products not recommended by NICE did not trigger an appraisal review.

Conclusions

Uncertainty, stemming from the lack of robust clinical data of products authorized with CMA/AEC, has a substantial impact on HTA recommendations, frequently requiring risk mitigation mechanisms such as commercial and data collection arrangements. Further analyses should be conducted to assess whether the benefits of early access strategies outweigh the risks for patients and the healthcare system.

Keywords

Drug approvalTechnology assessmentBiomedicalUncertaintyReimbursement mechanisms
Type
Policy
Information
International Journal of Technology Assessment in Health Care , Volume 36 , Issue 4 , August 2020 , pp. 426 - 433
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

European Network for Health Technology Assessment (EUnetHTA). What is health technology assessment (HTA)? 2018. Available from: https://www.eunethta.eu/services/submission-guidelines/submissions-faq/ (accessed 2019 Feb 05).Google Scholar
Chalkidou, K, Tunis, S, Lopert, R, Rochaix, L, Sawicki, PT, Nasser, M, et al. Comparative effectiveness research and evidence-based health policy: Experience from four countries. Milbank Q. 2009;87:339–67.Google ScholarPubMed
National Institute for Health and Care Excellence. NICE guidance; 2019. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance (accessed 2019 Feb 05)Google Scholar
Clement, FM, Harris, A, Li, JJ, Yong, K, Lee, KM, Manns, BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA. 2009;302:1437–43.CrossRefGoogle ScholarPubMed
European Medicines Agency. Conditional marketing authorisation; 1995–2018. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. Post-authorisation; 1995–2018. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. List of recommended technologies that include a commercial arrangement; 2019. Available from: https://www.nice.org.uk/About/What-we-do/Patient-access-schemes-liaison-unit/List-of-technologies-with-approved-Patient-Access-Schemes (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Cancer Drugs Fund; 2019. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/cancer-drugs-fund (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. Human regulatory; 1995–2018. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Guide to the processes of technology appraisal: Introduction; 2019. Available from: https://www.nice.org.uk/process/pmg19/chapter/introduction (accessed 2019 Feb 05).Google Scholar
StataCorp. Stata statistical software: Release 15. College Station, TX: StataCorp LLC; 2017.Google Scholar
European Medicines Agency. Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy; 1995–2018. Available from: https://www.ema.europa.eu/en/news/xigris-drotrecogin-alfa-activated-be-withdrawn-due-lack-efficacy (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. Onsenal (celecoxib): Withdrawal of the marketing authorisation in the European Union; 2011. Available from: https://www.ema.europa.eu/documents/public-statement/public-statement-onsenal-celecoxib-withdrawal-marketing-authorisation-european-union_en.pdf (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. Rilonacept Regeneron (Rilonacept): Withdrawal of the marketing authorisation in the European Union; 2012. Available from: https://www.ema.europa.eu/documents/public-statement/public-statement-rilonacept-regeneron-withdrawal-marketing-authorisation-european-union_en.pdf (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence (unknown) Technology Appraisals: Consultation on Batch 38 draft remits and draft scopes and summary of comments and discussions at scoping workshops; Available from: https://www.nice.org.uk/media/default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Block-scoping-reports/Batch%2038%20Block%20scoping%20report%20Web%20no%20CIC.pdf (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence (unknown) Technology Appraisals: Consultation on Batch 34 draft remits and draft scopes and summary of comments and discussions at scoping workshops; Available from: https://www.nice.org.uk/media/default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Block-scoping-reports/Batch-34-block-scoping-report.pdf (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Rapid re-consideration of drugs currently funded through the Cancer Drugs Fund; 2016. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/TA-CDF-reconsideration-process-March-2016-FINAL.pdf (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer; 2019. Available from: https://www.nice.org.uk/guidance/ta422/ (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Bosutinib for previously treated chronic myeloid leukaemia; 2016. Available from: https://www.nice.org.uk/guidance/ta401 (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma; 2019. Available from: https://www.nice.org.uk/guidance/ta178 (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy; 2019. Available from: https://www.nice.org.uk/guidance/ta242 (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab; 2019. Available from: https://www.nice.org.uk/guidance/ta202 (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. Onsenal (celecoxib): Sutent: Scientific discussion; 2011. Available from: https://www.ema.europa.eu/documents/scientific-discussion-variation/sutent-h-c-687-ii-0001-epar-scientific-discussion-variation_en.pdf (accessed 2019 Feb 05).Google Scholar
National Institute for Health and Care Excellence. Review of TA240; Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer, and TA242; Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy; 2015. Available from: https://www.nice.org.uk/guidance/ta242/documents/colorectal-cancer-metastatic-2nd-line-cetuximab-bevacizumab-and-panitumumab-review-appendix-a-rpp-decision-paper-march-20152 (accessed 2019 Feb 05).Google Scholar
European Medicines Agency (unknown) Arzerra (of atumumab): Assessment report: Arzerra; Available from: https://www.ema.europa.eu/en/documents/product-information/arzerra-epar-product-information_en.pdf (accessed 2019 Feb 05).Google Scholar
European Medicines Agency. ATryn Withdrawal of the marketing authorisation in the European Union; 2019. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-atryn-withdrawal-marketing-authorisation-european-union_en.pdf (accessed 2019 Aug 05)Google Scholar
European Medicines Agency. Arzerra Withdrawal of the marketing authorisation in the European Union; 2019. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-arzerra-withdrawal-marketing-authorisation-european-union_en.pdf (accessed 2019 Aug 05).Google Scholar
European Medicines Agency. Glybera Expiry of the marketing authorisation in the European Union; 2017. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-glybera-expiry-marketing-authorisation-european-union_en.pdf (accessed 2019 Aug 05).Google Scholar
European Medicines Agency. Conditional marketing authorisation: Report on ten years of experience at the European Medicines Agency; 2017. Available from: https://www.ema.europa.eu/documents/report/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf (accessed 2019 Feb 05).Google Scholar
Hoekman, J, Boon, WPC, Bouvy, JC, Ebbers, HC, de Jong, JP, De Bruin, ML. Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clin. Pharmacol. Ther. 2015;98:534–41.CrossRefGoogle ScholarPubMed
Hoekman, J, Boon, W. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union. Soc Sci Med. 2019;222:76–83.CrossRefGoogle ScholarPubMed
Hoekman, J, Klamer, TT, Mantel-Teeuwisse, AK, Leufkens, HG, De Bruin, ML. Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. Br J Clin Pharmacol. 2016;82:213–26.Google ScholarPubMed
Banzi, R, Gerardi, C, Bertele, V, Garattini, S. Approvals of drugs with uncertain benefit–risk profiles in Europe. Eur. J. Intern. Med. 2015;26:572–84.CrossRefGoogle ScholarPubMed
Naci, H, Smalley, KR, Kesselheim, AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. JAMA. 2017;318:626–36.CrossRefGoogle ScholarPubMed
Ermisch, M, Bucsics, A, Vella, BP, Arickx, F, Bybau, A, Bochenek, T, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front. Pharmacol. 2016;7:305.CrossRefGoogle ScholarPubMed
Lipska, I, Hoekman, J, McAuslane, N, Leufkens, HG, Hövels, AM. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions? Clin. Pharmacol. Ther. 2015;98:489–91.CrossRefGoogle ScholarPubMed
Vreman, RA, Bouvy, JC, Bloem, LT, Hövels, AM, Mantel-Teeuwisse, AK, Leufkens, H, et al. Weighing of evidence by health technology assessment bodies: Retrospective study of reimbursement recommendations for conditionally approved drugs. Clin. Pharmacol. Ther. 2018;0:1–8.Google Scholar
National Institute for Health and Care Excellence (unknown) Technology Appraisals recommendations; Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/data/appraisal-recommendations (accessed 2020 April 19).Google Scholar
Ferrario, A, Kanavos, P. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence. British National Formulary; 2009. Available from: https://bnf.nice.org.uk/ (accessed 2019 Feb 05).Google Scholar
NHS England (unknown) Commissioning; Available from: https://www.england.nhs.uk/commissioning/ (accessed 2019 Feb 05).Google Scholar
Monthly Index of Medical Specialities (unknown); Available from: https://www.mims.co.uk/ (accessed 2019 Feb 05).Google Scholar
National Health Service. Specialist Pharmacy Service; 2019. Available from: https://www.sps.nhs.uk/ (accessed 2019 Feb 05).Google Scholar
Supplementary material: File

Pinilla-Dominguez et al. supplementary material

Table S1

Download Pinilla-Dominguez et al. supplementary material(File)
File 30.7 KB
Supplementary material: File

Pinilla-Dominguez et al. supplementary material

Table S2

Download Pinilla-Dominguez et al. supplementary material(File)
File 20.6 KB